Drugs / IFN beta-1a
IFN beta-1a
also known as
Interferon beta-1a · FP-1201-lyo · IFN β-1a · Interferon (IFN) beta 1 a · IV IFN beta-1a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04860518 | Aug 2021 → Apr 2022 | COVID-19 | Faron Pharmaceuticals Ltd | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03387046 Background | Mar 2018 → Jan 2019 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01514370 Background | Apr 2012 → Mar 2016 | multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2022-03-14 | Faron Pharmaceuticals Ltd | Results Faron Publishes Research From INTEREST Trial faron.com ↗
A post hoc genetic analysis by the Company found that patients receiving Traumakine and carrying the SNP rs9984273 (C/T) in subunit 2 of INFAR2 showed a substantial reduction in mortality compared to patients without the gene mutation. |
| 2022-02-03 | Faron Pharmaceuticals Ltd | Results Scientific Reports Publishes INFORAAA Results faron.com ↗
today announces that the multidisciplinary journal Scientific Reports from the Nature Publishing Group published research highlighting results from Faron’s Phase II INFORAAA clinical trial. |
| 2021-01-26 | Faron Pharmaceuticals Ltd | Regulatory Update on TRAUMAKINE development faron.com ↗ |
| 2020-10-16 | Faron Pharmaceuticals Ltd | Results First Results from WHO Solidarity Trial faron.com ↗
The results show that subcutaneous interferon (IFN) beta-1a was found to be safe, but ineffective to reduce overall mortality in hospitalized patients with COVID-19. |
| 2020-05-20 | Faron Pharmaceuticals Ltd | Results Faron Pharmaceuticals Oy Harmful association of glucocorticoids in interferon beta-1a treated patients published in Intensive Care Medicine faron.com ↗
The results showed that the desired mechanism of action of IV IFN beta-1a in the lung vasculature – the upregulation of CD73 – is blocked by the administration of glucocorticoids. |
| 2020-03-09 | Faron Pharmaceuticals Ltd | Regulatory FDA accepts protocol for new Traumakine trial faron.com ↗
FDA accepts protocol for new Traumakine trial |
| 2019-06-14 | Faron Pharmaceuticals Ltd | Results Final results from YODA study faron.com ↗
The concomitant use of IFN beta-1a and prednisolone during part III reduced IFN beta-1a action, compared to subjects who received IFN beta-1a alone. |
| 2018-10-22 | Faron Pharmaceuticals Ltd | Results INTEREST trial update presented at ESICM faron.com ↗ |
| 2018-06-14 | Faron Pharmaceuticals Ltd | Results Biomarker analysis of Phase III INTEREST trial faron.com ↗ |
| 2018-05-08 | Faron Pharmaceuticals Ltd | Results Top line data from the Phase III INTEREST trial faron.com ↗
The INTEREST study did not meet the Day 28 (D28) primary efficacy composite endpoint of ventilator free days and survival with Traumakine treatment. |
| 2018-01-24 | Faron Pharmaceuticals Ltd | Regulatory FDA approval of Faron’s Traumakine® IND faron.com ↗ |
| 2016-01-07 | Faron Pharmaceuticals Ltd | Results Top-line results from Japanese study of Traumakine faron.com ↗
The all-cause mortality rate at Day 28, being the primary efficacy end point, was 22.2% across all patients (4/18). |
All press releases naming this drug 12 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IFN beta-1a | “40 subjects with Interferon (IFN) beta 1 a 44 mcg TIW + Curcumin (BCM 95) and 40 subjects with IFN beta-1a 44 mcg TIW + placebo.” NCT01514370 ↗ |
| Known as | FP-1201-lyo | “investigational new drug called FP-1201-lyo - intravenous Interferon beta-1a, hereafter IV IFN beta-1a” NCT04860518 ↗ |
| Known as | IFN β-1a | “Primary endpoint was the efficacy of curcumin versus placebo as add-on therapy on new/enlarging T2 lesions in RMS subjects under treatment with subcutaneous IFN β-1a 44 mcg TIW.” PMID 34583214 ↗ Sep 2021 |
| Known as | Interferon (IFN) beta 1 a | “40 subjects with Interferon (IFN) beta 1 a 44 mcg TIW + Curcumin (BCM 95) and 40 subjects with IFN beta-1a 44 mcg TIW + placebo.” NCT01514370 ↗ |
| Known as | Interferon beta-1a | “investigational new drug called FP-1201-lyo - intravenous Interferon beta-1a, hereafter IV IFN beta-1a” NCT04860518 ↗1“Interferon beta 1a” NCT01514370 ↗ |
| Known as | IV IFN beta-1a | “investigational new drug called FP-1201-lyo - intravenous Interferon beta-1a, hereafter IV IFN beta-1a” NCT04860518 ↗ |
| Modality | Protein / enzyme biologic | “intravenous recombinant human Interferon beta-1a” NCT04860518 ↗ |
| Route | Subcutaneous | “Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months.” NCT01514370 ↗ |